IBRX
ImmunityBio·NASDAQ
--
--(--)
--
--(--)
IBRX fundamentals
ImmunityBio (IBRX) Revenue Breakdown: Q3 2025 Business & Regional Performance
ImmunityBio (IBRX) reported total revenue of 32.06M USD in Q3 2025, with its core business segment Product contributing 99.12%. Regionally, United States remained the largest market, accounting for 99.18% of total revenue. Explore ImmunityBio's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
ImmunityBio (IBRX) reported total revenue of 32.06M USD in Q3 2025, with its core business segment Product contributing 99.12%. Regionally, United States remained the largest market, accounting for 99.18% of total revenue. Explore ImmunityBio's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
By Business
No Data
By Region
No Data
You can ask Aime
What is ImmunityBio's latest dividend and current dividend yield?Did ImmunityBio beat or miss consensus estimates last quarter?What guidance did ImmunityBio's management provide for the next earnings period?What were the key takeaways from ImmunityBio’s earnings call?What is the market's earnings forecast for ImmunityBio next quarter?What is ImmunityBio's gross profit margin?What does ImmunityBio do and what are its main business segments?What is the revenue and EPS growth rate for ImmunityBio year over year?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
